Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Chronic Urticaria
NCT06865651Phase 2Recruiting
- Sponsor
- Novartis
- Start
- May 2025
- Primary completion
- Aug 2027
- Countries
- 5
01
Overview
A Phase 2 trial of remibrutinib in chronic urticaria (CU), sponsored by Novartis. Started May 2025; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on NCT06865651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865651.